Analyst Price Targets — DARE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 24, 2024 7:45 am | Douglas Tsao | H.C. Wainwright | $12.00 | $3.50 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Dare Bioscience (DARE) |
Latest News for DARE
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses FDA clearance of the IND for DARE-HPV, the planned Phase 2 clinical study, and what the program could mean for women's health Access the segment here
DARE-HPV development supported by $10 million ARPA-H contract; program targets major unmet need with no FDA-approved therapies DARE-HPV development supported by $10 million ARPA-H contract; program targets major unmet need with no FDA-approved therapies
Dare Bioscience, Inc. (NASDAQ: DARE - Get Free Report) passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $2.10 and traded as low as $1.85. Dare Bioscience shares last traded at $1.95, with a volume of 78,714 shares traded. Analysts Set New
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DARE.
U.S. House Trading
No House trades found for DARE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.